Intra-Op Liberal Fluid Therapy Effectively Cuts Post-Op Nausea

This article originally appeared here.
Share this content:
Intra-Op Liberal Fluid Therapy Effectively Cuts Post-Op Nausea
Intra-Op Liberal Fluid Therapy Effectively Cuts Post-Op Nausea

MONDAY, June 12, 2017 (HealthDay News) -- For children undergoing lower abdominal surgery, intraoperative liberal fluid therapy is effective for reducing postoperative nausea and vomiting (PONV), according to a study published online June 6 in Pediatric Anesthesia.

Vighnesh Ashok, from the Post Graduate Institute of Medical Education and Research in Chandigarh, India, and colleagues examined the effects of intraoperative liberal fluid therapy with crystalloids on PONV in children aged 3 to 7 years. Participants were undergoing lower abdominal and penile surgery under general anesthesia and were randomized to either a restricted group, receiving 10 mL/kg/hour, or a liberal group, receiving 30 mg/kg/hour infusion of Ringer's lactate solution intraoperatively.

The researchers found that the incidence of PONV was significantly less in the liberal versus the restricted group (27.4 versus 45.8 percent of patients had vomiting, respectively; relative risk, 0.59). The adjusted odds ratio for PONV was 2.24 for the liberal versus the restricted group. During the first six postoperative hours, the incidence of fluid intake was significantly higher in patients in the restricted group; 83 and 17 percent of children in the restricted versus the liberal group complained of thirst (relative risk, 0.19). Satisfaction was higher for parents of patients in the liberal versus the restricted group (mean difference, −0.9). There were no complications attributed to liberal fluid therapy.

"Liberal intraoperative fluid therapy was found to be effective in reducing PONV in children undergoing lower abdominal surgery," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »